Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1987 1
1991 2
1992 2
1999 3
2000 1
2001 2
2002 1
2003 3
2004 3
2005 2
2006 6
2007 3
2008 12
2009 9
2010 9
2011 9
2012 9
2013 9
2014 13
2015 10
2016 13
2017 13
2018 12
2019 10
2020 10
2021 9
2022 13
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, Assi E, Seelam AJ, El Essawy B, Jang J, Loretelli C, D'Addio F, Berra C, Ben Nasr M, Zuccotti G, Fiorina P. Bendotti G, et al. Among authors: lunati me. Pharmacol Res. 2022 Aug;182:106320. doi: 10.1016/j.phrs.2022.106320. Epub 2022 Jun 20. Pharmacol Res. 2022. PMID: 35738455 Review.
Anti-diabetic drugs and weight loss in patients with type 2 diabetes.
Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, Vallone L, Bolla AM, Rossi A, Montefusco L, Ippolito E, Berra C, D'Addio F, Zuccotti GV, Fiorina P. Lazzaroni E, et al. Among authors: lunati me. Pharmacol Res. 2021 Sep;171:105782. doi: 10.1016/j.phrs.2021.105782. Epub 2021 Jul 22. Pharmacol Res. 2021. PMID: 34302978 Free article.
SGLT2-inhibitors are effective and safe in the elderly: The SOLD study.
Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P. Lunati ME, et al. Pharmacol Res. 2022 Sep;183:106396. doi: 10.1016/j.phrs.2022.106396. Epub 2022 Aug 12. Pharmacol Res. 2022. PMID: 35970329
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule.
Ben Nasr M, Usuelli V, Dellepiane S, Seelam AJ, Fiorentino TV, D'Addio F, Fiorina E, Xu C, Xie Y, Balasubramanian HB, Castillo-Leon E, Loreggian L, Maestroni A, Assi E, Loretelli C, Abdelsalam A, El Essawy B, Uccella S, Pastore I, Lunati ME, Sabiu G, Petrazzuolo A, Ducci G, Sacco E, Centofanti L, Venturini M, Mazzucchelli S, Mattinzoli D, Ikehata M, Castellano G, Visner G, Kaifeng L, Lee KM, Wang Z, Corradi D, La Rosa S, Danese S, Yang J, Markmann JF, Zuccotti GV, Abdi R, Folli F, Fiorina P. Ben Nasr M, et al. Among authors: lunati me. Cell Metab. 2024 Jun 4;36(6):1302-1319.e12. doi: 10.1016/j.cmet.2024.05.001. Cell Metab. 2024. PMID: 38838642
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.
Lunati ME, Cimino V, Bernasconi D, Gandolfi A, Morpurgo PS, Tinari C, Lazzaroni E, Baruffaldi L, Muratori M, Montefusco L, Pastore I, Rossi A, Franzetti IG, Muratori F, Manfrini R, Disoteo OE, Terranova R, Desenzani P, Girelli A, Ghelardi R, D'Addio F, Ben Nasr M, Berra C, Folli F, Bucciarelli L, Fiorina P. Lunati ME, et al. Pharmacol Res. 2024 Jan;199:107040. doi: 10.1016/j.phrs.2023.107040. Epub 2023 Dec 20. Pharmacol Res. 2024. PMID: 38128857 Free article.
eATP and autoimmune diabetes.
Loretelli C, Pastore I, Lunati ME, Abdelsalam A, Usuelli V, Assi E, Fiorina E, Loreggian L, Balasubramanian HB, Xie Y, Yang J, El Essawy B, Montefusco L, D'Addio F, Ben Nasr M, Fiorina P. Loretelli C, et al. Among authors: lunati me. Pharmacol Res. 2023 Apr;190:106709. doi: 10.1016/j.phrs.2023.106709. Epub 2023 Feb 25. Pharmacol Res. 2023. PMID: 36842542 Free article. Review.
The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
Bendotti G, Montefusco L, Pastore I, Lazzaroni E, Lunati ME, Fiorina P. Bendotti G, et al. Among authors: lunati me. J Endocrinol Invest. 2023 Dec;46(12):2445-2452. doi: 10.1007/s40618-023-02162-9. Epub 2023 Aug 3. J Endocrinol Invest. 2023. PMID: 37535237 Review.
Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease.
Petrazzuolo A, Sabiu G, Assi E, Maestroni A, Pastore I, Lunati ME, Montefusco L, Loretelli C, Rossi G, Ben Nasr M, Usuelli V, Xie Y, Balasubramanian HB, Zocchi M, El Essawy B, Yang J, D'Addio F, Fiorina P. Petrazzuolo A, et al. Among authors: lunati me. Pharmacol Res. 2023 Apr;190:106710. doi: 10.1016/j.phrs.2023.106710. Epub 2023 Mar 4. Pharmacol Res. 2023. PMID: 36871895 Free article. Review.
Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).
Berra CC, Rossi MC, Mirani M, Ceccarelli Ceccarelli D, Romano C, Sassi L, Peretti E, Favacchio G, Pastore I, Folini L, Graziano G, Lunati ME, Solerte SB, Fiorina P. Berra CC, et al. Among authors: lunati me. Front Endocrinol (Lausanne). 2023 Jan 18;13:1099451. doi: 10.3389/fendo.2022.1099451. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36743930 Free PMC article.
183 results